LY2835219 free base

• CAT Number: I000911
• CAS Number: 1231929-97-7
• Molecular Formula: C27H32F2N8
• Molecular Weight: 506.60
• Purity: ≥95%
• Synonyms: N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
• Target: CDK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 2 nM(CDK4); 10 nM(CDK6)
• IUPAC Name: N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
• InChI: InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
• InChIKey: UZWDCWONPYILKI-UHFFFAOYSA-N
• SMILES: CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F

LY2835219 free base（Cat No.:I000911）, also known as Abemaciclib, is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting these kinases, it prevents phosphorylation of the retinoblastoma protein (Rb), leading to cell cycle arrest in the G1 phase. This mechanism makes it highly effective in targeting cancers driven by dysregulated CDK4/6 activity, particularly hormone receptor-positive breast cancer. LY2835219 is used in cancer research and therapy to inhibit tumor growth and is often administered in combination with hormonal therapies for improved efficacy.

Reference

[1]. Patrick J. Roberts, John E. Bisi, Jay C. Strum, et al. Two trials of other CDK4/6 inhibitors (NVP-LEE011 and LY2835219) have begun enrolling cancer patients for phase I clinical testing. JNCI J Natl Cancer Inst (2012) 104 (6): 476-487.
[2]. CDK4/6 dual inhibitor LY2835219
[3]. A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
[4]. Study of LY2835219 for Mantle Cell Lymphoma